Blincyto blinatumomab availability in Indian Marke

Blincyto (blinatumomab) is prescribed for adult and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It works by directing T-cells to target cancerous B-cells. The Blincyto blinatumomab availability in India is limited to import under the Named Patient Program (NPP), as it is not commercially registered here. Our facilitation team assists hospitals and oncologists in sourcing Blincyto from trusted international suppliers approved by regulatory authorities. We ensure compliance with CDSCO guidelines, handle import licensing, and maintain temperature-sensitive logistics from origin to destination. This service is intended for eligible patients under the supervision of their treating physician. Please call/WhatsApp: +91 8130290915 for detailed guidance on Blincyto availability and import assistance.